IMPLICATIONS OF FLEROXACINS PHARMACOKINETIC PROFILE

被引:1
|
作者
NIGHTINGALE, CH
机构
[1] Hartford Hospital, Hartford, CT 06115
关键词
FLEROXACIN; PHARMACODYNAMICS; ELIMINATION; ABSORPTION; BODY DISTRIBUTION; DRUG INTERACTIONS;
D O I
10.1016/0924-8579(94)90016-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Fleroxacin, like all quinolones, is well absorbed, reaching peak concentrations within 2 h. Interactions with Ca2+ and Al3+ are minimal compared with other quinolones and possibly of little clinical importance. The drug is eliminated via filtration in the kidney. It is therefore sensitive to changes in renal function. Accumulation of drug in the body is minimal, and change from intravenous to oral dosing results in nearly identical serum concentrations. Aside from the modest effect of metals on its absorption, fleroxacin does not interact/compete with substances oxidized in the liver, such as theophylline, and drug interactions are minimal. Its long serum half-life (8-12 h) allows once-a-day dosing. This may be of particular pharmacodynamic advantage when treating infections caused by organisms with relatively high MIC's. This feature, along with its modest drug interactions, indicates that fleroxacin will probably be an important quinolone useful in a variety of clinical settings.
引用
收藏
页码:S7 / S13
页数:7
相关论文
共 50 条
  • [31] The pharmacokinetic and pharmacodynamic profile of tigecycline
    Meagher, AK
    Ambrose, PG
    Grasela, TH
    Ellis-Grosse, EJ
    CLINICAL INFECTIOUS DISEASES, 2005, 41 : S333 - S340
  • [32] Pharmacokinetic profile of oral tazarotene
    Yu, D
    Ni, JS
    Attar, M
    Tang-Liu, D
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P147 - P147
  • [33] Pharmacokinetic/pharmacodynamic profile of voriconazole
    Theuretzbacher, Ursula
    Ihle, Franziska
    Derendorf, Hartmut
    CLINICAL PHARMACOKINETICS, 2006, 45 (07) : 649 - 663
  • [34] Pharmacokinetic profile of spectinomycin in rats
    Madhura, D. B.
    Lee, R.
    Meibohm, B.
    PHARMAZIE, 2013, 68 (08): : 675 - 676
  • [35] Meropenem pharmacokinetic profile in cats
    Albarellos, G. A.
    Montoya, L.
    Quaine, P. C.
    Lupi, M. P.
    Passini, S.
    Denamiel, G. A.
    Landoni, M. F.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2012, 35 : 103 - 103
  • [36] Pharmacokinetic profile of atenolol aspirinate
    Montes-Gil, Ana C.
    Zanfolin, Marcos
    Okuyama, Cristina E.
    Lilla, Sergio
    Alves, Delma P.
    Santagada, Vincenzo
    Perissutti, Elisa
    Lavecchia, Antonio
    Fiorino, Ferdinando
    Severino, Beatrice
    Caliendo, Giuseppe
    Priviero, Fernanda B. M.
    Mendes, Gustavo D.
    Donato, Jose L.
    de Nucci, Gilberto
    ARCHIV DER PHARMAZIE, 2007, 340 (09) : 445 - 455
  • [37] PHARMACOKINETIC PROFILE OF FOSFOMYCIN TROMETAMOL
    BERGAN, T
    THORSTEINSSON, SB
    ALBINI, E
    CHEMOTHERAPY, 1993, 39 (05) : 297 - 301
  • [38] Pharmacokinetic and pharmacodynamic profile of ceftobiprole
    Lodise, Thomas P.
    Patel, Nimish
    Renaud-Mutart, Amy
    Gorodecky, Evgeny
    Fritsche, Thomas R.
    Jones, Ronald N.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 61 (01) : 96 - 102
  • [39] Pharmacokinetic/Pharmacodynamic Profile of Voriconazole
    Ursula Theuretzbacher
    Franziska Ihle
    Hartmut Derendorf
    Clinical Pharmacokinetics, 2006, 45 : 649 - 663
  • [40] PHARMACOKINETIC PROFILE OF CEFOTAXIME IN GOATS
    ATEF, M
    RAMADAN, A
    AFIFI, NA
    YOUSSEF, SAH
    DEUTSCHE TIERARZTLICHE WOCHENSCHRIFT, 1990, 97 (08): : 324 - 327